Battle Against Johnson & Johnson "Texas Two-Step" Ploy Moves to New Jersey

In a new state court filing, women who hold Johnson & Johnson (NYSE:JNJ) and the company's iconic talc baby powder responsible for their ovarian cancer are seeking a temporary restraining order and preliminary injunction to prevent J&J, or any of its corporate affiliates, from fraudulently transferring assets to a subsidiary and plunging it into bankruptcy.

Faced with more than 34,000 ovarian cancer lawsuits, many consolidated in New Jersey federal court, J&J has told attorneys for the victims that the company is actively exploring options to transfer its potential talc-related liabilities – valued at approximately $24 billion – to a stand-alone subsidiary and seek bankruptcy protection for that business entity. Such a move would limit compensation for victims to pennies on the dollar and could bring an indefinite halt to all related trials scheduled in state courts across the nation, as well as the federal multidistrict litigation being heard in Trenton.

In a motion filed in Superior Court of New Jersey , attorneys for the plaintiffs argue that the bankruptcy strategy violates fraudulent conveyance laws in New Jersey and most other states. However, under a scheme known in legal circles as the "Texas Two-Step," economically viable companies can incorporate in Texas and then transfer liabilities to another entity with limited or no assets. As a result, a new company could be created by J&J to hold all legal liabilities but with limited or no funds to pay litigation claims.

In one recent case, In re DBMP LLC , U.S. Bankruptcy Judge J. Craig Whitley , in the Western District of North Carolina , was critical of the "Two Step" practice. In recent years, other companies such as Georgia-Pacific LLC have shifted asbestos liabilities to a separate company - with few if any assets - before placing it in bankruptcy.

"Plaintiffs deserve to have their day in court before a judge and jury, not arbitrarily placed in bankruptcy court with little hope of adequate compensation," says Andy Birchfield , Mass Tort Section Head of the Beasley Allen law firm , which represents thousands of ovarian cancer victims. "Bankruptcy should not be used as a ploy to delay or deny justice for the victims of a dangerous product produced by a company with hundreds of billions of dollars in assets."

The filing in New Jersey answers J&J complaints that a similar previous petition in Missouri unfairly burdened the company. "We'll take this cause to J&J's backyard where it cannot hide and avoid what is obviously a need for judicial oversight and intervention," says Michelle Parfitt , co-lead counsel in the Talcum Powder MDL and Senior Partner at Ashcraft and Gerel , who also represents the plaintiffs.

Dozens of peer-reviewed medical studies published in the last 35 years have found a statistically significant correlation between talcum powder use and ovarian cancer. Further research has confirmed that talc particles, when applied to the perineal area, can migrate to the ovaries, and result in inflammation and related malignancies. In December 2018 , Reuters reported that J&J knew for decades that its talc products were laced with asbestos but kept that information from regulators and the public.

"Companies that are bursting at the seams with available cash cannot be allowed to abuse the bankruptcy system this way," says Alexandra Walsh , founder of Walsh Law . "Make no mistake; this case is a wake-up call to anyone who is concerned about the rights of individuals, the right to trial by jury and the belief that huge corporations must play by the rules and accept responsibility when they commit wrong."

In May 2020 , Johnson & Johnson announced the company would no longer make nor market talc-based powders for the North American market.

In June, the U.S. Supreme Court declined to hear an appeal resulting from a $2.1 billion judgment against the company entered by the Missouri Court of Appeals and upheld by the Missouri Supreme Court. That appellate court found that J&J had engaged in "reprehensible conduct" for decades by repeatedly denying the presence of asbestos and the known association between talc use and ovarian cancer.

Media Contact:
Mike Androvett
214-507-5456
mike@androvett.com

Cision View original content: https://www.prnewswire.com/news-releases/battle-against-johnson--johnson-texas-two-step-ploy-moves-to-new-jersey-301368796.html

SOURCE Beasley Allen Law Firm

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO

"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic announces cash dividend for third quarter of fiscal year 2025

The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0 .70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025 to shareholders of record at the close of business on December 27, 2024 .

About Medtronic
Bold thinking. Bolder actions. We are Medtronic . Medtronic plc , headquartered in Galway , Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic , visit www.Medtronic.com and follow Medtronic on LinkedIn .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiex Limited (ASX:CDX)

Cardiex Limited


Keep reading...Show less

Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation Awareness Day

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support to the many patients impacted by OIC

"As an organization dedicated to supporting individuals living with pain conditions, we're proud to participate in this year's OIC Awareness Day," said Kathy Sapp, CEO of ACPA. "By increasing awareness and improving communication between healthcare providers, patients, and caregivers, we can make a meaningful difference for those affected by this commonly occurring condition."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected

FN Media Group News Commentary - Innovations in robotics technology, including artificial intelligence machine learning, and sensor technology, are enhancing the capabilities of medical robots. These advancements enable more precise surgical procedures, improved rehabilitation processes, and efficient hospital logistics, thus attracting more healthcare facilities to adopt robotic solutions. The market is characterized by a moderate level of merger and acquisition (M&A) activity by the leading players. This is due to several factors, including the desire to expand the business to cater to the growing demand for medical service robots. A report from Grand View Research said that the global medical service robots market size was estimated at USD 20.59 billion in 2024 and is projected to grow at a CAGR of 16.5% from 2025 to 2030. It said: "The growth can be attributed to the introduction of technologically advanced robotic equipment in the healthcare sector and the rise in per capita healthcare spending. Continuous advancements in technology, such as robotic catheter control systems (CCS), data recorders, data analytics, remote navigation, motion sensors, 3D-Imaging, and HD surgical microscopic cameras, are projected to drive industry growth. Furthermore, the introduction of swarm robotics is opening new opportunities for industry. It is a new approach to coordinating multi-robotic systems through swarm intelligence." Active Tech Companies in the markets today include Jeffs' Brands Ltd (NASDAQ: JFBR), Serve Robotics Inc. (NASDAQ: SERV), Symbotic Inc. (NASDAQ: SYM), Microbot Medical Inc. (NASDAQ: MBOT), Medtronic plc (NYSE: MDT).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×